Back to search

France· FR:61001565

ITOVEBI 3 mg, comprimé pelliculé

A inavolisib product containing inavolisib, registered in France by ROCHE REGISTRATION (ALLEMAGNE). The same ATC class is registered in 10 of our 19 countries.

ATC L01EM06

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedITOVEBI 3 mg, comprimé pelliculéATCL01EM06REGISTER NO.FR:61001565PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Inavolisib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EM06 (inavolisib), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Inavolisib · ATC L01EM06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
INAVOLISIB
Manufacturer
ROCHE REGISTRATION (ALLEMAGNE)
Country
France (FR)
ATC code
L01EM06
ATC class
Inavolisib
Defined daily dose
9 mg, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930320983
    plaquette(s) aluminium de 28 comprimé(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Inavolisib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inavolisib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Itovebi
  • Liechtenstein · Itovebi
  • Norway · Itovebi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2cff2f5e-3edf-42fe-a6b8-78735592972a
GET /v1/drugs/2cff2f5e-3edf-42fe-a6b8-78735592972a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61001565",
  "date_amm": "2025-07-18",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/25/1942",
  "substance": "INAVOLISIB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about inavolisib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.